TITLE

The EBMT activity survey 2008: impact of team size, team density and new trends

AUTHOR(S)
Gratwohl, A.; Baldomero, H.; Schwendener, A.; Gratwohl, M.; Apperley, J.; Frauendorfer, K.; Niederwieser, D.
PUB. DATE
February 2011
SOURCE
Bone Marrow Transplantation;Feb2011, Vol. 46 Issue 2, p174
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Six hundred and fifteen centers from 45 countries reported a total 30 293 HSCT to this 2008 EBMT survey with 26 810 first transplants (40% allogeneic, 60% autologous). This corresponds to an increase of 7% for the allogeneic and 3% for the autologous HSCT. Main indications were leukemias (32%; 89% allogeneic); lymphomas (56%; 89% autologous); solid tumors (6%; 96% autologous); and non-malignant disorders (6%; 88% allogeneic). There were more unrelated than HLA-identical sibling donors (49 vs 46%). The proportion of peripheral blood transplants remained stable with 99% for autologous and 70% for allogeneic HSCT. One fifth of the teams with >80 HSCT performed more than half of all HSCT. This trend towards teams with higher numbers of HSCT was stronger for allogeneic (Gini coefficient 57%) than for autologous HSCT (Gini coefficient 38%). Transplant rates (number of transplants per 10 million inhabitants) increased in a close to linear way with increasing team density (number of transplant teams per 10 million inhabitants) and without saturation (R2=0.54); this connection was even stronger for allogeneic HSCT (R2=0.67). These data illustrate status and trends for HSCT in Europe. They provide a rational basis for planning and patient counseling.
ACCESSION #
57985654

 

Related Articles

  • Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age. Ringdén, O; Remberger, M; Mattsson, J; Aschan, J; Carlens, S; Hägglund, H; Lönnqvist, B; Sparrelid, E; Ljungman, P // Bone Marrow Transplantation;1/1/98, Vol. 21 Issue 1, p43 

    Twenty-seven patients above 40 years of age (range 40–55) with leukaemia underwent transplantation with haematopoietic stem cells from HLA-A, -B and -DR identical unrelated donors. They were compared to 69 younger patients, median age 23. In the older group, the diagnoses were acute...

  • 13. Minitransplants.  // Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS145 

    Bone Marrow Transplantation (2001) 29, Suppl. 2, S145–S154. DOI: 10.1038/sj/bmt/1703478

  • Hematopoietic stem cell transplantation in Lebanon: first comprehensive report. Bazarbachi, A.; Hatoum, H. A.; Mugharbel, A.; Otrock, Z. K.; Yassine, N.; Muwakkit, S.; Salem, Z.; Shebbo, W.; Jisr, T.; Abboud, M.; Ibrahim, A. // Bone Marrow Transplantation;Aug2008 Supplement, Vol. 42, pS96 

    Hematopoietic SCT (HSCT) has become a curative therapeutic strategy for several malignant and nonmalignant diseases. We report the comprehensive results of the first 10 years of experience in HSCT from the two major BMT units in Lebanon: Makassed University Hospital and the American University...

  • Oral Sessions and Working Parties.  // Bone Marrow Transplantation;Apr2013 Supplement, Vol. 48, pS6 

    The article presents abstracts on medical topics including "Introduction and update on the EBMT Acute Leukaemia Working Party activities," by M. Mohty, M. Lobopin and S. Giebel, "Haplo donors for all: are we there," by F. Ciceri, N.-C. Gorin and M. Mohty and "High dose TBI for conditioning prior...

  • EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation. Wang, H-t; Chang, Y-j; Xu, L-p; Liu, D-h; Wang, Y; Liu, K-y; Huang, X-j // Bone Marrow Transplantation;Jul2014, Vol. 49 Issue 7, p927 

    Systematic, standardised pretransplant risk assessment is an important tool for predicting patient outcomes following allogeneic haematopoietic SCT (HSCT). To assess the European Group for Blood and Marrow Transplantation (EBMT) risk score capacities for predicting patient outcomes following...

  • Stem cell registry collaboration will help save more lives.  // British Journal of Hospital Medicine (17508460);Feb2012, Vol. 73 Issue 2, p71 

    The article reports that a new system, operated by Anthony Nolan, and National Health Service (NHS) Blood and Transplant, manages the British bone marrow registry and cord blood banks which fasten the process of finding a potential donor match, benefiting leukaemia and other blood cancer patients.

  • Evolution of nutritional status in patients with autologous and allogeneic hematopoietic stem cell transplant. Defranchi, Romina; Bordalejo, Andrea; Cañueto, Inés; Villar, Angeles; Navarro, Elizabet // Supportive Care in Cancer;May2015, Vol. 23 Issue 5, p1341 

    Purpose: To describe the nutritional status in patients undergoing hematopoietic stem cell transplant (HSCT) in three different defined moments: at admission to the Bone Marrow Transplant Unit (BMTU), at discharge from the BMTU and at follow-up. We hypothesized that nutrition status declines...

  • Acute Myeloid Leukaemia of Donor Cell Origin Developing 17 Years after Allogenic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukaemia. Jiménez, Pilar; Alvarez, J. Carlos; Garrido, Pilar; Lorente, J. Antonio; Palacios, Jorge; Ruiz-Cabello, Francisco // International Journal of Biomedical Science;Dec2012, Vol. 8 Issue 4, p244 

    Donor cell leukaemia (DCL) is a rare complication of allogenic hematopoietic cell transplantation (HCT). We report the case of a female patient with acute promyelocytic leukaemia (APL), FAB type M3, who devel­oped acute myeloid leukaemia (AML) type M5 of donor origin 17 years after allogenic...

  • Allogeneic matched-sibling hematopoietic cell transplantation for AML: comparable outcomes between Eastern Mediterranean (EMBMT) and European (EBMT) centers. Bazarbachi, A; Labopin, M; Ghavamzadeh, A; Giebel, S; Al-Zahrani, H; Ladeb, S; Leone, G; Abdel-Rahman, F; Liso, V; Hamidieh, A A; Rasheed, W; Ibrahim, A; Alabdulaaly, A; Kyrcz-Krzemien, S; Arnold, R; Kharfan-Dabaja, M A; Alimoghaddam, K; Aljurf, M; Mohty, M // Bone Marrow Transplantation;Aug2013, Vol. 48 Issue 8, p1065 

    Allogeneic hematopoietic cell transplantation (HCT) activity significantly increased in the Eastern Mediterranean area over the past decade. However, comparative outcomes with longer established centers, especially European Blood and Marrow Transplantation (EBMT) centers, have not been reported....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics